|
RECONCILIATION OF SEGMENT PRE-TAX OPERATING
INCOME (PTOI) TO OPERATING EARNINGS (dollars in millions) Industrial
Biosciences 2014 2013 Segment PTOI (GAAP) 198 170 Add: Significant Items
Charge/ (Benefit) included in Segment PTOI 13 (1) Segment Operating Earnings
(Non-GAAP) 211 169 FORWARD LOOKING STATEMENTS This document contains
forward-looking statements which may be identified by their use of words like
plans, expects, will, believes, intends, estimates, anticipates
or other words of similar meaning. All statements that address expectations
or projections about the future, including statements about the companys
strategy for growth, product development, regulatory approval, market
position, anticipated benefits of recent acquisitions, timing of anticipated
benefits from restructuring actions, outcome of contingencies, such as
litigation and environmental matters, expenditures and financial results, are
forward looking statements. Forward-looking statements are not guarantees of
future performance and are based on certain assumptions and expectations of
future events which may not be realized. Forward-looking statements also
involve risks and uncertainties, many of which are beyond the companys
control. Some of the important factors that could cause the companys actual
results to differ materially from those projected in any such forward-looking
statements are: fluctuations in energy and raw material prices; failure to
develop and market new products and optimally manage product life cycles;
ability to respond to market acceptance, rules, regulations and policies
affecting products based on biotechnology; significant litigation and
environmental matters; failure to appropriately manage process safety and
product stewardship issues; changes in laws and regulations or political
conditions; global economic and capital markets conditions, such as
inflation, interest and currency exchange rates; business or supply
disruptions; security threats, such as acts of sabotage, terrorism or war, weather
events and natural disasters; ability to protect and enforce the companys
intellectual property rights; successful integration of acquired businesses
and separation of underperforming or non-strategic assets or businesses and
successful completion of the proposed spinoff of the Performance Chemicals
segment including ability to fully realize the expected benefits of the
proposed spinoff. The company undertakes no duty to update any
forward-looking statements as a result of future developments or new information.
ADDITIONAL INFORMATION AND WHERE TO FIND IT DuPont has filed a definitive
proxy statement with the U.S. Securities and Exchange Commission (the SEC)
with respect to the 2015 Annual Meeting. DUPONT STOCKHOLDERS ARE STRONGLY
ENCOURAGED TO READ THE DEFINITIVE PROXY STATEMENT (INCLUDING ANY AMENDMENTS
AND SUPPLEMENTS), THE ACCOMPANYING WHITE PROXY CARD AND OTHER DOCUMENTS FILED
WITH THE SEC CAREFULLY IN THEIR ENTIRETY BECAUSE THEY CONTAIN IMPORTANT
INFORMATION. DuPont, its directors, executive officers and other employees
may be deemed to be participants in the solicitation of proxies from DuPont
stockholders in connection with the matters to be considered at DuPonts 2015
Annual Meeting. Information about DuPonts directors and executive officers
is available in DuPonts definitive proxy statement, filed with the SEC on
March 23, 2015, for its 2015 Annual Meeting. To the extent holdings of
DuPonts securities by such directors or executive officers have changed
since the amounts printed in the proxy statement, such changes have been or
will be reflected on Statements of Change in Ownership on Form 4 filed with
the SEC. Information regarding the identity of potential participants, and
their direct or indirect interests, by security holdings or otherwise, is set
forth in the definitive proxy statement and, to the extent applicable, will
be updated in other materials to be filed with the SEC in connection with
DuPonts 2015 Annual Meeting. Stockholders will be able to obtain any proxy
statement, any amendments or supplements to the proxy statement and other
documents filed by DuPont with the SEC free of charge at the SECs website at
www.sec.gov. Copies also will be available free of charge at DuPonts website
at www.dupont.com or by contacting DuPont Investor Relations at (302)
774-4994. # # # 4/16/15
|